
SpringWorks Therapeutics SWTX
SpringWorks Therapeutics EV/EBITDA Ratio | SWTX
Annual EV/EBITDA Ratio SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.3 | -9.33 | -6.1 | -15.3 | -73.2 K | -2.04 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.04 | -73.2 K | -12.2 K |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Savara
SVRA
|
-9.6 | $ 4.92 | -2.57 % | $ 1.09 B | ||
|
Teligent, Inc.
TLGT
|
2.8 | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
-1.96 | - | - | $ 2.91 B | ||
|
TG Therapeutics
TGTX
|
37.9 | $ 64.27 | 1.4 % | $ 9.28 B | ||
|
Aphria Inc.
APHA
|
-117 | - | -0.45 % | $ 4.87 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
-3.41 | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
-2.73 | - | -6.00 % | $ 238 M | ||
|
Trevi Therapeutics
TRVI
|
-30.5 | $ 14.92 | -2.55 % | $ 2.01 B | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
-5.12 | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
27.1 | - | 0.38 % | $ 12.9 M | ||
|
AzurRx BioPharma, Inc.
AZRX
|
-0.000002 | - | 2.07 % | $ 34.4 M | ||
|
Cerecor Inc.
CERC
|
-4.65 | - | -1.68 % | $ 283 M | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
-11.6 | - | - | $ 1.63 B | ||
|
Auris Medical Holding Ltd.
EARS
|
0.463 | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
-14.4 | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
5.22 | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
-110 | - | - | $ 6.81 B | ||
|
Kadmon Holdings, Inc.
KDMN
|
-7.37 | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
-0.811 | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
38.2 | $ 972.42 | 1.05 % | $ 59.6 B | ||
|
XBiotech
XBIT
|
0.841 | $ 1.97 | 3.2 % | $ 60.1 M | ||
|
Neos Therapeutics, Inc.
NEOS
|
-17.5 | - | -2.54 % | $ 57.2 M | ||
|
Odonate Therapeutics, Inc.
ODT
|
-4.74 | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
0.718 | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
16.1 | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
-11.2 | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
0.897 | $ 1.76 | -2.09 % | $ 2.99 M | ||
|
Viridian Therapeutics
VRDN
|
-8.14 | $ 30.86 | 2.22 % | $ 3.14 B | ||
|
Translate Bio, Inc.
TBIO
|
350 | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
-14 | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
-1.91 K | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-47 | - | - | $ 10.9 B | ||
|
Zealand Pharma A/S
ZEAL
|
-0.823 | - | 0.52 % | $ 821 M | ||
|
Zogenix, Inc.
ZGNX
|
-4.47 | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
44 | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
-8.58 | - | -7.58 % | $ 264 M | ||
|
Xenon Pharmaceuticals
XENE
|
-6.03 | $ 41.4 | 2.35 % | $ 3.28 B | ||
|
Leap Therapeutics
LPTX
|
0.106 | - | 368.57 % | $ 41.9 M | ||
|
Zymeworks
ZYME
|
-3.7 | $ 31.45 | 2.08 % | $ 1.62 B | ||
|
Adial Pharmaceuticals
ADIL
|
0.407 | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
19.2 | $ 12.67 | -0.98 % | $ 3.02 B | ||
|
Cortexyme
CRTX
|
-2.13 | - | -1.05 % | $ 67.1 M | ||
|
Burford Capital Limited
BUR
|
24.7 | $ 3.66 | -1.35 % | $ 802 M | ||
|
Daré Bioscience
DARE
|
-1.83 | $ 0.69 | 1.75 % | $ 7.71 M | ||
|
Fate Therapeutics
FATE
|
-1.04 | $ 1.78 | -8.51 % | $ 211 M | ||
|
Greenwich LifeSciences
GLSI
|
-19.8 | $ 16.05 | -2.85 % | $ 217 M | ||
|
Halozyme Therapeutics
HALO
|
25 | $ 103.0 | 0.08 % | $ 12.3 B | ||
|
Hutchison China MediTech Limited
HCM
|
-481 | $ 15.34 | 0.1 % | $ 13.2 B | ||
|
Aptorum Group Limited
APM
|
29.7 | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
-2.85 | $ 0.78 | -1.89 % | $ 81.2 M |